William S. Marth became President and CEO of Albany Molecular Research, Inc. in January 2014, after briefly serving as the company's non-executive Chairman. In 2013, Mr. Marth served as a senior advisor to Teva Pharmaceuticals following his retirement in 2012 as President and Chief Executive Officer of Teva – Americas. He had previously served as President and Chief Executive Officer of Teva North America from January 2008 to June 2010, as President and Chief Executive Officer of Teva USA from January 2005 to January 2008 and Executive Vice President and Vice President of Sales and Marketing for Teva USA. In addition Bill worked with several large equity firms providing guidance on their healthcare investments.
Mr. Marth is recognized as an industry leader with an unparalleled record of commercial success. He was a key strategist in establishing Teva as a leading Specialty Pharmaceutical Company and being ultimately recognized as the worldwide #1 producer of generic drugs. Responsibilities include heading the respiratory, neuroscience, oncology and women’s healthcare divisions plus Select Brands. He was a member of Teva’s global executive management team and Teva Americas’ board of directors from 2007 to 2012. His experience is Global in all core functional areas including Strategic Planning, IR, R&D, Supply Chain Management and Regulatory. He also served as the architect of the $6.8 billion Cephalon and $7.4 billion Barr Laboratories transactions and integrations. Prior to joining Teva USA, he held various positions with the Apothecon division of Bristol-Myers Squibb.
Mr. Marth earned his B.Sc. in Pharmacy from the University of Illinois in 1977, his M.B.A. in 1989 from the Keller Graduate School of Management, DeVry University and an honorary D.H.L. from the Albany College of Pharmacy and Health Sciences in 2015. He is a licensed pharmacist and has served on various boards and committees, including The University of the Sciences in Philadelphia, the Board of Ambassadors for John Hopkins’ Project RESTORE. In January of 2014, Mr. Marth became the Chairman of the Board of Directors of Sorrento Therapeutics and in March of 2014 became a Director at Galmed Pharmaceuticals. Mr. Marth served as the Chairman of the Board of the Generic Pharmaceutical Association (GPhA) in 2008 and 2009 and the American Society for Health-System Pharmacists (ASHP) in 2010.